| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary target of Mesitaldehyde is DPP-IV (dipeptidyl peptidase IV), an enzyme involved in glucose metabolism and the development of diabetic neuropathy. As an endogenous metabolite, it may interact with various physiological pathways. The compound is a carbonyl compound that is used in biochemical experiments and drug synthesis. These targets make it relevant for research on diabetes, diabetic neuropathy, and metabolic disorders.
|
|---|---|
| ln Vitro |
In vitro, Mesitaldehyde demonstrates DPP-IV inhibitory activity, suggesting potential applications in diabetes research. The compound is widely used in biochemical experiments. It is studied in vitro to understand its effects on DPP-IV activity and glucose metabolism. As a carbonyl compound, it may participate in various chemical and biochemical reactions. These in vitro activities support its use in diabetes research, drug discovery, and biochemical studies.
|
| ln Vivo |
In vivo, Mesitaldehyde has potential therapeutic applications in the treatment of diabetic neuropathy due to its DPP-IV inhibitory activity. However, detailed in vivo efficacy data are limited. As an endogenous metabolite, it is naturally present in biological systems. Further studies are needed to evaluate its therapeutic potential in animal models of diabetes and diabetic neuropathy. The compound is primarily used as a research tool for biochemical and drug synthesis studies.
|
| Enzyme Assay |
In vitro enzyme assays for Mesitaldehyde involve measuring DPP-IV inhibition. The compound is incubated with DPP-IV enzyme at concentrations ranging from 0.1-1000 μM, and enzyme activity is measured using chromogenic or fluorogenic substrates. IC50 values are determined by plotting percent inhibition versus inhibitor concentration. The compound's reactivity as a carbonyl compound may be assessed using standard chemical assays. All assays include appropriate controls and reference compounds (e.g., known DPP-IV inhibitors such as sitagliptin).
|
| Cell Assay |
In vitro cell-based assays for Mesitaldehyde are conducted using cell lines relevant to diabetes research (e.g., pancreatic beta cells or intestinal cells). Cells are treated with compound concentrations ranging from 0.1-1000 μM for 24-72 hours. DPP-IV activity is measured in cell lysates or conditioned media. Glucose uptake and metabolism are assessed. Cell viability is assessed using MTT assays. Experiments include vehicle controls and positive controls (e.g., known DPP-IV inhibitors).
|
| Animal Protocol |
In vivo animal studies with Mesitaldehyde are limited, as the compound is primarily used as a research tool. Diabetes studies may be conducted in rodent models of type 2 diabetes or diabetic neuropathy. The compound is administered via intraperitoneal or oral routes at doses ranging from 1-50 mg/kg. Blood glucose levels are measured. DPP-IV activity is assessed in plasma or tissue samples. Neuropathy endpoints may be evaluated. Each group consists of 6-10 animals with vehicle-treated controls.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Mesitaldehyde have not been extensively characterized. As a small, lipophilic molecule (MW 148.20, C10H12O), it is expected to have good oral bioavailability and tissue distribution. The compound is an endogenous metabolite and likely undergoes hepatic metabolism through oxidation and conjugation, with elimination via renal excretion. Detailed PK parameters such as half-life, Cmax, and AUC require further investigation.
|
| Toxicity/Toxicokinetics |
Toxicological data for Mesitaldehyde indicate that it is generally well-tolerated at concentrations used for research. As an endogenous metabolite, it is expected to have a favorable safety profile. No significant toxicity has been reported. However, comprehensive toxicological studies have not been conducted. As with all research chemicals, appropriate safety precautions should be taken during handling, and the compound should be used only for research purposes.
|
| Additional Infomation |
2,4,6-Trimethylbenzaldehyde is a carbonyl compound.
Mesitaldehyde (2,4,6-Trimethylbenzaldehyde) is an endogenous metabolite with DPP-IV inhibitory activity. It has been studied for potential therapeutic applications in diabetic neuropathy. The compound is widely used in biochemical experiments and drug synthesis research. It is a carbonyl compound that serves as a research tool for diabetes, metabolic disorders, and drug discovery. Not approved for clinical therapeutic use; intended for research purposes only. |
| Molecular Formula |
C10H12O
|
|---|---|
| Molecular Weight |
148.20168
|
| Exact Mass |
148.088
|
| CAS # |
487-68-3
|
| PubChem CID |
10254
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
241.5±9.0 °C at 760 mmHg
|
| Melting Point |
10-12 °C(lit.)
|
| Flash Point |
105.6±0.0 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.546
|
| LogP |
3.02
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
130
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=CC1=C(C)C=C(C)C=C1C
|
| InChi Key |
HIKRJHFHGKZKRI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H12O/c1-7-4-8(2)10(6-11)9(3)5-7/h4-6H,1-3H3
|
| Chemical Name |
2,4,6-trimethylbenzaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~674.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (8.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (8.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (8.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.7476 mL | 33.7382 mL | 67.4764 mL | |
| 5 mM | 1.3495 mL | 6.7476 mL | 13.4953 mL | |
| 10 mM | 0.6748 mL | 3.3738 mL | 6.7476 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
